ClinicalTrials.gov Search Results 04/15/2020

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
1	NCT04328493	The Vietnam Chloroquine Treatment on COVID-19 Study Documents:	Title Acronym: VICO Other Ids: COVID	Not yet recruiting	•SARS-CoV-2 Infection •COVID-19	•Drug: Chloroquine phosphate	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Viral clearance time •Lengh of hospital stay •Ventilator free days •Oxygene free days •Time to death •Adverse events •Time to viral PCR negative from rectal swab •fever clearance time •Ordinal outcome scale •Development of ARDS	Enrollment: 250 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Oxford University Clinical Research Unit, Vietnam •Ministry of Health, Vietnam •Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam •Cu Chi COVID Hospital, Vietnam •Can Gio COVID Hospital, Vietnam •Cho Ray Hospital, Vietnam •National Hospital for Tropical Diseases, Hanoi, Vietnam •Department of Health, Ho Chi Minh city	•Other	Study Start: April 1, 2020 Primary Completion: April 1, 2021 Study Completion: April 1, 2022 First Posted: March 31, 2020 Results First Posted: No Results Posted Last Update Posted: March 31, 2020	•National Hospital for Tropical Diseases, Hanoi, Vietnam •Can Gio COVID Hospital, Ho Chi Minh City, Vietnam •Cho Ray Hospital, Ho Chi Minh City, Vietnam •Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam •Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
2	NCT04303507	Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting Study Documents:	Title Acronym: COPCOV Other Ids: VIR20001	Not yet recruiting	•COVID19 •Coronavirus •Acute Respiratory Illnesses	•Drug: Chloroquine or Hydroxychloroquine •Drug: Placebo	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Prevention Outcome Measures: •Number of symptomatic COVID-19 infections •Symptoms severity of COVID-19 •Number of asymptomatic cases of COVID-19 •Number of symptomatic acute respiratory illnesses •Severity of symptomatic acute respiratory illnesses	Enrollment: 40000 Age: 16 Years and older (Child, Adult, Older Adult) Sex: All	•University of Oxford	•Other	Study Start: April 2020 Primary Completion: April 2021 Study Completion: April 2021 First Posted: March 11, 2020 Results First Posted: No Results Posted Last Update Posted: March 27, 2020	
3	NCT04331600	ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020 Study Documents:	Title Acronym: QUARANTINE2020 Other Ids: QUARANTINE2020	Not yet recruiting	•COVID-19	•Drug: Chloroquine phosphate •Other: Telemedicine	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •COVID-19-related hospitalization or all-cause death •Decrease in COVID-19 symptoms •Development of pneumonia •Development of coronavirus infection-related complications	Enrollment: 400 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Wroclaw Medical University	•Other	Study Start: April 6, 2020 Primary Completion: September 30, 2020 Study Completion: December 31, 2020 First Posted: April 2, 2020 Results First Posted: No Results Posted Last Update Posted: April 2, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
4	NCT04333628	Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 Study Documents:	Title Acronym: Other Ids: EMC 0045-20	Not yet recruiting	•COVID-19	•Drug: chloroquine •Other: standard care	Study Type: Interventional Phase: •Phase 2 •Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •change in virus duration (viral shedding) •change in the number of patients going from asymptomatic to moderately disease	Enrollment: 210 Age: 18 Years and older (Adult, Older Adult) Sex: All	•HaEmek Medical Center, Israel •T MAY BIOPHARMA LTD.	•Other	Study Start: April 2020 Primary Completion: April 2021 Study Completion: December 2021 First Posted: April 3, 2020 Results First Posted: No Results Posted Last Update Posted: April 14, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
5	NCT04344951	Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial Study Documents:	Title Acronym: HOPE Other Ids: UNIKINON-01/ HOPE	Recruiting	•Pneumonia, Viral •Covid-19	•Drug: UNIKINON (Chloroquine phosphate) 200mg tablets	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Prevention Outcome Measures: •50% reduction in symptom score for patients with lower respiratory tract infection •Lack of progression for patients with upper respiratory tract infection •Comparison of the primary endpoint with respective patients not receiving the treatment •Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment. •Frequency of AEs and SAEs	Enrollment: 60 Age: 18 Years to 90 Years (Adult, Older Adult) Sex: All	•Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. •Athens General Hospital Hippokrateio •Athens General Hospital of Thoracic Diseases SOTIRIA •General Hospital of Athens Sismanoglio •Divine Providence Hospital Pammakaristos	•Industry •Other	Study Start: April 6, 2020 Primary Completion: April 1, 2021 Study Completion: April 30, 2021 First Posted: April 14, 2020 Results First Posted: No Results Posted Last Update Posted: April 14, 2020	•Divine Providence Hospital "Pammakaristos", Athens, Greece •Athens General Hospital "Hippokrateio", Athens, Greece •Athens General Hospital of Thoracic Diseases "SOTIRIA", 1st University Pulmonary Clinic, Athens, Greece •Athens General Hospital of Thoracic Diseases "SOTIRIA", 3rd University Pathology Clinic, Athens, Greece •General Hospital of Athens "Sismanoglio", Maroúsi, Greece

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
6	NCT04333732	CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION Study Documents:	Title Acronym: CROWN CORONA Other Ids: 202004099	Not yet recruiting	•COVID 19	•Drug: Low-dose chloroquine/ hydroxychloroquine •Drug: Mid dose chloroquine or hydroxychloroquine •Drug: High does chloroquine or hydroxychloroquine •Drug: Placebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Prevention Outcome Measures: •Symptomatic COVID-19 •Peak severity of COVID-19 over the study period	Enrollment: 55000 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Washington University School of Medicine •Bill and Melinda Gates Foundation	•Other	Study Start: April 2020 Primary Completion: February 2021 Study Completion: February 2021 First Posted: April 3, 2020 Results First Posted: No Results Posted Last Update Posted: April 15, 2020	•Washington University School of Medicine, Saint Louis, Missouri, United States •Melbourne Medical School, Melbourne, Victoria, Australia •Population Health Resarch Institute, Hamilton, Ontario, Canada •University of Toronto, Toronto, Ontario, Canada •St James's Hospital, Dublin, Leinster, Ireland •Universitas Academic Hospital, Bloemfontein, Free State, South Africa •Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa •Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa •Tygerberg Hospital, Cape Town, Western Cape, South Africa •Groote Schuur Hospital, Cape Town, Western Cape, South Africa •University College London, London, United Kingdom •Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
7	NCT04323527	Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 Study Documents:	Title Acronym: CloroCOVID19 Other Ids: CAAE: 30152620.1.0000.00	Recruiting	•SARS-CoV Infection •Severe Acute Respiratory Syndrome (SARS) Pneumonia	•Drug: Chloroquine diphosphate	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Mortality rate reduction of 50% by day 28 •Absolute mortality on days 7 and 14 •Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28 •Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization •Duration of supplemental oxygen (if applicable) •Duration of mechanical ventilation (if applicable) •Absolute duration of hospital stay in days •Prevalence of grade 3 and 4 adverse events •Prevalence of serious adverse events •Change in serum creatinine level •and 6 more	Enrollment: 440 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Fundação de Medicina Tropical Dr. Heitor Vieira Dourado •Marcus Vinícius Guimarães de Lacerda •Mayla Gabriela Silva Borba •Wuelton Marcelo Monteiro •Gisely Cardoso de Melo •Fernando Fonseca de Almeida e Val •Felipe Gomes Naveca •Maria Paula Gomes Mourão •Ludmila Abrahão Hajjar •Jorge Souza Mendonça	•Other	Study Start: March 23, 2020 Primary Completion: August 31, 2020 Study Completion: August 31, 2020 First Posted: March 26, 2020 Results First Posted: No Results Posted Last Update Posted: April 15, 2020	•Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
8	NCT04324463	Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial Study Documents:	Title Acronym: ACT COVID19 Other Ids: PHRI.ACT.COVID19	Not yet recruiting	•Coronavirus •Severe Acute Respiratory Syndrome	•Drug: Azithromycin •Drug: Chloroquine	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Outpatients: Hospital Admission or Death •Inpatients: Invasive mechanical ventilation or mortality	Enrollment: 1500 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Population Health Research Institute	•Other	Study Start: April 1, 2020 Primary Completion: September 30, 2020 Study Completion: December 31, 2020 First Posted: March 27, 2020 Results First Posted: No Results Posted Last Update Posted: March 27, 2020	•Hamilton Health Sciences, Hamilton, Ontario, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
9	NCT04342650	Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection Study Documents:	Title Acronym: CloroCOVID19II Other Ids: CAAE: 30504220.5.0000.00	Recruiting	•COVID-19 •SARS-CoV Infection •Severe Acute Respiratory Syndrome (SARS) Pneumonia •Clinical Trial	•Drug: Chloroquine Diphosphate •Drug: Placebo oral tablet	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Proportion of patients with onset of severe acute respiratory syndrome (SARS) •Mortality rate •Number of participants in need of intensive care support •Viral concentration •Cumulative incidence of serious adverse events •Cumulative incidence of grade 3 and 4 adverse events •Proportion of patients with discontinued treatment •Incidence of cardiac lesions •Incidence of cardiac disfunctions •Change in respiratory capacity	Enrollment: 210 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	•Other	Study Start: April 8, 2020 Primary Completion: September 2020 Study Completion: September 2020 First Posted: April 13, 2020 Results First Posted: No Results Posted Last Update Posted: April 14, 2020	•Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
10	NCT04316377	Norwegian Coronavirus Disease 2019 Study Study Documents:	Title Acronym: NO COVID-19 Other Ids: REC 121446	Recruiting	•Corona Virus Infection	•Drug: Hydroxychloroquine Sulfate	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Rate of decline in SARS-CoV-2 viral load •Change in National Early Warning Score score •Admission to intensive care unit •In-hospital mortality •Duration of hospital admission •Mortality at 30 and 90 days •Clinical status	Enrollment: 202 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Akershus	•Other	Study Start: March 25, 2020 Primary Completion: April 1, 2021 Study Completion: March 3, 2025 First Posted: March 20, 2020 Results First Posted: No Results Posted Last Update Posted: April 3, 2020	•Akershus University Hospital, Lørenskog, Norway

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
11	NCT04333914	Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection Study Documents:	Title Acronym: IMMUNONCOVID Other Ids: •ET20-076 - IMMUNONCOVID-2 •2020-001373-70	Recruiting	•SARS-CoV-2 (COVID-19) Infection •Advanced or Metastatic Hematological or Solid Tumor	•Drug: Chloroquine analog (GNS651) •Drug: Nivolumab •Drug: Tocilizumab •Other: Standard of care	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •28-day survival rate •Time to clinical improvement •Clinical status •Mean change in clinical status from baseline to days •Overall survival •Length of stay in Intensive Care Unit •Duration of mechanical ventilation or high flow oxygen devices •Duration of hospitalization •Rate of throat swab negativation •Quantitative SARS-CoV-2 virus in throat swab and blood samples •and 4 more	Enrollment: 273 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Centre Leon Berard	•Other	Study Start: April 2020 Primary Completion: June 2020 Study Completion: August 2020 First Posted: April 3, 2020 Results First Posted: No Results Posted Last Update Posted: April 7, 2020	•Centre Léon Bérard, Lyon, Rhône, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
12	NCT04286503	The Clinical Study of Carrimycin on Treatment Patients With COVID-19 Study Documents: •Study Protocol •Informed Consent Form	Title Acronym: Other Ids: BeijingYouan Hospital	Not yet recruiting	•Novel Coronavirus Infectious Disease (COVID-19)	•Drug: Carrimycin •Drug: lopinavir/ ritonavir tablets or Arbidol or chloroquine phosphate •Drug: basic treatment	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Fever to normal time (day) •Pulmonary inflammation resolution time (HRCT) (day) •Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment	Enrollment: 520 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•Beijing YouAn Hospital •Shenyang Tonglian Group Co., Ltd. •Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences •Huangshi Central Hospital •Shenyang Pharmaceutical University •First Affiliated Hospital of Chongqing Medical University •The Second Affiliated Hospital of Harbin Medical University •No.2 People's Hospital of Fuyang City •First Affiliated Hospital Bengbu Medical College •Renmin Hospital of Wuhan University •The sixth people's hospital of Shenyang •Nanyang Central Hospital	•Other	Study Start: February 23, 2020 Primary Completion: February 28, 2021 Study Completion: February 28, 2021 First Posted: February 27, 2020 Results First Posted: No Results Posted Last Update Posted: February 27, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
13	NCT04322396	Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19 Study Documents:	Title Acronym: ProPAC-COVID Other Ids: KronLungesyg_COV	Recruiting	•Virus Diseases •Infection Viral •Corona Virus Infection	•Drug: Azithromycin •Drug: Hydroxychloroquine •Drug: Placebo oral tablet	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Number of days alive and discharged from hospital within 14 days •Categorization of hospitalization status •Admitted to intensive care unit, if admitted to ICU then length of stay •Have used Non-invasive ventilation (NIV) during hospitalization •Mortality •Length of hospitalization •Days alive and discharged from hospital •Number of readmissions (all causes) •Number of days using non-invasive ventilation (NIV) •Change in patient's oxygen partial pressure •and 3 more	Enrollment: 226 Age: Child, Adult, Older Adult Sex: All	•Chronic Obstructive Pulmonary Disease Trial Network, Denmark	•Other	Study Start: April 6, 2020 Primary Completion: October 31, 2020 Study Completion: March 31, 2021 First Posted: March 26, 2020 Results First Posted: No Results Posted Last Update Posted: April 13, 2020	•Aalborg Sygehus, Aalborg, Denmark •Bispebjerg Hospital, Copenhagen, Denmark •Herlev-Gentofte Hospital, Copenhagen, Denmark •Hvidovre Hospital, Copenhagen, Denmark •Nordsjællands Hospital, Hillerød, Denmark •Odense Universitetshospital, Odense, Denmark •Roskilde Sygehus, Roskilde, Denmark •Slagelse Sygehus, Slagelse, Denmark

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
14	NCT04346667	Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds Study Documents:	Title Acronym: PEACE Other Ids: NBC-COVID19-02	Not yet recruiting	•SARS-CoV-2 •Coronavirus Infection •Asymptomatic Condition •COVID-19	•Drug: Hydroxychloroquine Sulfate Regular dose •Drug: Hydroxychloroquine Sulfate Loading Dose •Drug: Chloroquine •Drug: Placebo	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •RT-PCR negative status •Progression of symptoms •Development of Symptoms •Adverse events	Enrollment: 400 Age: 20 Years to 50 Years (Adult) Sex: All	•Government of Punjab, Specialized Healthcare and Medical Education Department •Mayo Hospital Lahore •Services Institute of Medical Sciences, Pakistan •Pakistan Kidney and Liver Institute •Forman Christian College •Harvard School of Public Health	•Other	Study Start: April 14, 2020 Primary Completion: April 28, 2020 Study Completion: May 28, 2021 First Posted: April 15, 2020 Results First Posted: No Results Posted Last Update Posted: April 15, 2020	
15	NCT04341727	Hydroxychloroquine,Hydroxychlorin the Treatment of SARS CoV-2 Infection Study Documents:	Title Acronym: WU352 Other Ids: 202003188	Recruiting	•Coronavirus Infection	•Drug: Hydroxychloroquine Sulfate •Drug: Azithromycin •Drug: Chloroquine Sulfate	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Hours to recovery •Time fever resolution	Enrollment: 500 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Washington University School of Medicine	•Other	Study Start: April 4, 2020 Primary Completion: April 1, 2021 Study Completion: August 1, 2021 First Posted: April 10, 2020 Results First Posted: No Results Posted Last Update Posted: April 10, 2020	•Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States •Washington University School of Medicine, Saint Louis, Missouri, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
16	NCT04346329	Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19 Study Documents:	Title Acronym: Chloroquine UN Other Ids: UNAL-COVID-CP	Not yet recruiting	•COVID	•Drug: Hydroxychloroquine •Drug: Placebo oral tablet	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Care Provider) •Primary Purpose: Prevention Outcome Measures: •Adverse effects •Immune-score •COVID-19 prevention •Clinical response	Enrollment: 86 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Universidad Nacional de Colombia •Fundación Salud de los Andes	•Other	Study Start: April 20, 2020 Primary Completion: June 1, 2020 Study Completion: October 1, 2020 First Posted: April 15, 2020 Results First Posted: No Results Posted Last Update Posted: April 15, 2020	•Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia •Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia
17	NCT04345419	A Real-life Experience on Treatment of Patients With COVID 19 Study Documents:	Title Acronym: Other Ids: COVID 19 treatment	Not yet recruiting	•COVID	•Drug: Chloroquine •Drug: Favipiravir •Drug: Nitazoxanide •Drug: Ivermectin •Drug: Niclosamide	Study Type: Interventional Phase: •Phase 2 •Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Participant) •Primary Purpose: Treatment Outcome Measures: Number of patients with decreased viral load	Enrollment: 100 Age: Child, Adult, Older Adult Sex: All	•Tanta University	•Other	Study Start: April 15, 2020 Primary Completion: December 2029 Study Completion: December 2029 First Posted: April 14, 2020 Results First Posted: No Results Posted Last Update Posted: April 14, 2020	•Tanta university hospital, Tanta, Egypt

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
18	NCT04345406	Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19 Study Documents:	Title Acronym: Other Ids: ACEIS COVID 19	Not yet recruiting	•COVID	•Drug: ACEIs •Drug: Conventional treatment	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: number of patients with virological cure	Enrollment: 60 Age: Child, Adult, Older Adult Sex: All	•Tanta University	•Other	Study Start: April 15, 2020 Primary Completion: December 1, 2029 Study Completion: December 1, 2029 First Posted: April 14, 2020 Results First Posted: No Results Posted Last Update Posted: April 14, 2020	•Tanta University, Tanta, Egypt
19	NCT04331470	Evaluation of Efficacy of Levamisole and Formoterol +Budesonide in Treatment of COVID-19 Study Documents:	Title Acronym: Other Ids: 97548	Recruiting	•COVID-19	•Drug: Levamisole Pill + Budesonide +Formoterol inhaler •Drug: Lopinavir/ Ritonavir + hydoxychloroquine	Study Type: Interventional Phase: •Phase 2 •Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Clear chest CT-scan •PCR test •Physical statues of patient	Enrollment: 30 Age: 15 Years to 100 Years (Child, Adult, Older Adult) Sex: All	•Fasa University of Medical Sciences	•Other	Study Start: April 4, 2020 Primary Completion: April 20, 2020 Study Completion: May 20, 2020 First Posted: April 2, 2020 Results First Posted: No Results Posted Last Update Posted: April 13, 2020	•Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
20	NCT04304053	Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention Study Documents:	Title Acronym: HCQ4COV19 Other Ids: •HCQ4COV19 •2020-001031-27	Recruiting	•COVID-19	•Drug: Antiviral treatment and prophylaxis •Other: Standard Public Health measures	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Prevention Outcome Measures: •Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases •The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3 •The mortality rate of subjects at weeks 2 •Proportion of participants that drop out of study •Proportion of participants that show non-compliance with study drug	Enrollment: 3040 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Fundacio Lluita Contra la SIDA •Germans Trias i Pujol Hospital •Department of Health, Generalitat de Catalunya •FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA •Laboratorios Gebro Pharma SA •Laboratorios Rubió •Institut Catala de Salut	•Other	Study Start: March 18, 2020 Primary Completion: June 15, 2020 Study Completion: June 15, 2020 First Posted: March 11, 2020 Results First Posted: No Results Posted Last Update Posted: April 8, 2020	•Departament de Salut, Barcelona, Spain

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
21	NCT04323345	Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus Study Documents:	Title Acronym: Other Ids: MUST23032020	Not yet recruiting	•COVID-19	•Dietary Supplement: Natural Honey •Other: Standard Care	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Investigator) •Primary Purpose: Treatment Outcome Measures: •Rate of recovery from positive to negative swaps •Fever to normal temperature in days •Resolution of lung inflammation in CT or X ray •30 days mortality rate •Number of days till reaching negative swab results	Enrollment: 1000 Age: 5 Years to 75 Years (Child, Adult, Older Adult) Sex: All	•Misr University for Science and Technology	•Other	Study Start: March 25, 2020 Primary Completion: April 25, 2020 Study Completion: May 10, 2020 First Posted: March 26, 2020 Results First Posted: No Results Posted Last Update Posted: March 26, 2020	•Mahmoud Tantawy, Cairo, Egypt
22	NCT04330144	Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial) Study Documents:	Title Acronym: Other Ids: 3-2020-0036	Not yet recruiting	•Contact Person From COVID-19 Confirmed Patient	•Drug: Hydroxychloroquine as post exposure prophylaxis •Other: Others(No intervention)	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Prevention Outcome Measures: The rate of COVID-19	Enrollment: 2486 Age: 18 Years to 99 Years (Adult, Older Adult) Sex: All	•Gangnam Severance Hospital	•Other	Study Start: April 1, 2020 Primary Completion: March 30, 2021 Study Completion: March 30, 2022 First Posted: April 1, 2020 Results First Posted: No Results Posted Last Update Posted: April 1, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
23	NCT04343677	Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study Study Documents:	Title Acronym: Other Ids: Pentagon 20-1	Not yet recruiting	•COVID-19	•Drug: Hydroxychloroquine •Dietary Supplement: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Prevention Outcome Measures: •Incidence •Severity of Disease	Enrollment: 1450 Age: 18 Years and older (Adult, Older Adult) Sex: All	•United States Department of Defense	•U.S. Fed	Study Start: April 2020 Primary Completion: June 2020 Study Completion: August 2020 First Posted: April 13, 2020 Results First Posted: No Results Posted Last Update Posted: April 13, 2020	•Pentagon, Arlington, Virginia, United States
24	NCT04333355	Safety in Convalescent Plasma Transfusion to COVID-19 Study Documents:	Title Acronym: Other Ids: PC-TecSalud Fase I	Not yet recruiting	•COVID-19	•Biological: Convalescent Plasma	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Side effects •Heart Failure •Pulmonary Edema •Allergic Reaction •Lung infiltrates •Viral load of SARS-CoV-2	Enrollment: 20 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Hospital San Jose Tec de Monterrey •Tecnologico de Monterrey	•Other	Study Start: April 15, 2020 Primary Completion: December 20, 2020 Study Completion: April 30, 2021 First Posted: April 3, 2020 Results First Posted: No Results Posted Last Update Posted: April 3, 2020	•Hospital San José, Monterrey, Nuevo Leon, Mexico

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
25	NCT04340544	Hydroxychloroquine for the Treatment of Mild COVID-19 Disease Study Documents:	Title Acronym: COMIHY Other Ids: COMIHY	Not yet recruiting	•COVID-19	•Drug: Hydroxychloroquine •Drug: Placebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment •Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered) •All-cause mortality within 28 days	Enrollment: 2700 Age: 18 Years to 99 Years (Adult, Older Adult) Sex: All	•University Hospital Tuebingen •Robert Bosch Medical Center •Universitätskliniku Hamburg-Eppendorf •Bernhard Nocht Institute for Tropical Medicine	•Other	Study Start: April 10, 2020 Primary Completion: November 30, 2021 Study Completion: September 30, 2022 First Posted: April 9, 2020 Results First Posted: No Results Posted Last Update Posted: April 9, 2020	•Institute for Tropical Medicine, Tübingen, Germany

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
26	NCT04342221	Hydroxychloroquine for COVID-19 Study Documents:	Title Acronym: COV-HCQ Other Ids: •COV-HCQ •2020-001224-33	Recruiting	•COVID-19, Hydroxychloroquine Sulfate	•Drug: Hydroxychloroquine Sulfate •Drug: Placebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: Effect of HCQ on in vivo viral clearance	Enrollment: 220 Age: 18 Years to 99 Years (Adult, Older Adult) Sex: All	•University Hospital Tuebingen •Robert Bosch Medical Center •Universitätsklinikum Hamburg-Eppendorf •Bernhard Nocht Institute for Tropical Medicine	•Other	Study Start: March 29, 2020 Primary Completion: March 2021 Study Completion: February 2022 First Posted: April 10, 2020 Results First Posted: No Results Posted Last Update Posted: April 10, 2020	•Institute for Tropical Medicine, Tübingen, Germany
27	NCT04321278	Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) Study Documents:	Title Acronym: Other Ids: 30155020.5.1001.00	Recruiting	•Coronavirus Infections •Pneumonia, Viral	•Drug: Hydroxychloroquine + azithromycin •Drug: Hydroxychloroquine	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Evaluation of the clinical status •All-cause mortality •Number of days free from mechanical ventilation •Duration of mechanical ventilation •Duration of hospitalization •Other secondary infections •Time from treatment start to death	Enrollment: 440 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Hospital Israelita Albert Einstein •EMS •Hospital do Coracao •Hospital Sirio-Libanes •Brazilian Research In Intensive Care Network •Cristália Produtos Químicos Farmacêuticos Ltda.	•Other •Industry	Study Start: March 28, 2020 Primary Completion: August 30, 2020 Study Completion: August 30, 2020 First Posted: March 25, 2020 Results First Posted: No Results Posted Last Update Posted: April 1, 2020	•Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil •Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil •Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil •Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil •Universidade Estadual de Londrina, Londrina, Paraná, Brazil •Hospital Universitário Onofre Lopes, Natal, Rio Grande Do Norte, Brazil •Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil •Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil •Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil •Fundação Pio XII, Barretos, São Paulo, Brazil •and 12 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
28	NCT04347512	Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia Study Study Documents:	Title Acronym: TEACHCOVID Other Ids: 7783	Not yet recruiting	•Sars-CoV-2, Community-Acquired Pneumonia	•Drug: Hydroxychloroquine and azithromycin treatment arm. •Drug: Hydroxychloroquine •Drug: Control arm	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Rate of patients reaching a significant hypoxemia, in each arms.	Enrollment: 405 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Strasbourg, France	•Other	Study Start: May 1, 2020 Primary Completion: August 1, 2021 Study Completion: August 1, 2021 First Posted: April 15, 2020 Results First Posted: No Results Posted Last Update Posted: April 15, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
29	NCT04325893	Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease Study Documents:	Title Acronym: HYCOVID Other Ids: 49RC20_0071	Recruiting	•Coronavirus	•Drug: Hydroxychloroquine •Drug: Placebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment. •Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment. •Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14 •Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28. •Number of all-cause mortality at day 14 •Number of all-cause mortality at day 28 •Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5 •Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10 •The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee. •Number of all-cause mortality at day 28 in patients aged 75 and older •and 3 more	Enrollment: 1300 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Angers	•Other	Study Start: April 2020 Primary Completion: September 2020 Study Completion: September 2020 First Posted: March 30, 2020 Results First Posted: No Results Posted Last Update Posted: April 8, 2020	•CH Agen, Agen, France •CHU Amiens, Amiens, France •CHU Angers, Angers, France •APHP Avicenne, Bobigny, France •CHU Brest, Brest, France •CHU Caen, Caen, France •CH Cherbroug, Cherbourg, France •CH Cholet, Cholet, France •CH Colmar, Colmar, France •APHP Henri Mondor, Créteil, France •and 27 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
30	NCT04335305	Checkpoint Blockade in COVID-19 Pandemic Study Documents:	Title Acronym: COPERNICO Other Ids: MedOPP376	Recruiting	•COVID-19 •Pneumonia, Viral	•Drug: Tocilizumab •Biological: Pembrolizumab (MK-3475)	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Percentage of patients with normalization of SpO2 #96% •Proportion of patients with temperature < 37,5 °C armpit. •Proportion of patients discharged from the emergency department and classified as low risk •Change from baseline in organ failure parameters •Proportion of mortality rate •Analysis of the remission of respiratory symptoms •Evaluation of the radiological response •Time to first negative in SARS-CoV-2 RT-PCR test •Change from baseline of ALC (absolute lymphocyte count),white blood cell count and white blood cell differential count •Change from baseline of hemoglobin •and 8 more	Enrollment: 24 Age: 18 Years and older (Adult, Older Adult) Sex: All	•MedSIR	•Other	Study Start: April 14, 2020 Primary Completion: May 15, 2020 Study Completion: May 15, 2020 First Posted: April 6, 2020 Results First Posted: No Results Posted Last Update Posted: April 15, 2020	•Hospital Quirónsalud Barcelona, Barcelona, Spain •Hospital de la Santa Creu i Sant Pau, Barcelona, Spain •Hospital Ruber Juan Bravo, Madrid, Spain •Hospital Ruber Internacional, Madrid, Spain •Hospital Arnau de Vilanova-Lliria, Valencia, Spain •Hospital Universitario Doctor Peset, Valencia, Spain

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
31	NCT04323592	Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome Study Documents: •Study Protocol and Statistical Analysis Plan •Informed Consent Form	Title Acronym: MP-C19 Other Ids: MP-19 023_2020	Recruiting	•Severe Acute Respiratory Syndrome (SARS) Pneumonia •Coronavirus Infections •ARDS, Human	•Drug: Methylprednisolone •Other: standard care	Study Type: Interventional Phase: •Phase 2 •Phase 3 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Composite primary end-point •death •Admission to ICU •Endotracheal intubation (invasive mechanical ventilation) •reduction of C-reactive protein or CRP •Reduction of mechanical ventilation	Enrollment: 104 Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All	•University of Trieste	•Other	Study Start: March 23, 2020 Primary Completion: May 20, 2020 Study Completion: May 30, 2020 First Posted: March 26, 2020 Results First Posted: No Results Posted Last Update Posted: March 27, 2020	•Marco Confalonieri, Trieste, TS, Italy